title: Glaucoma: an extension of various chronic neurodegenerative disorders.
abstract: The eyes are the window of the brain; various pathologies of the eyes can be explained on the basis of neurological disorders and vice versa. Today, our only approach for the management of glaucoma is intraocular pressure (IOP) reduction, whether by pharmacological or surgical methods. Available methods may effectively control IOP but fall short of stopping the progression of glaucoma. IOP is just one of the risk factors our therapy addresses, so we need to work towards shifting our approach towards addressing other factors involved in the etiopathogenesis of the disease. Pathogenesis of glaucoma at molecular level can be compared with that of common neurodegenerative diseases like Alzheimer's and Parkinsonism. Targets for therapeutic intervention in chronic neurodegenerative diseases and glaucoma include apoptosis, axonal transport, free radical damage, role of polyunsaturated fatty acids, chaperones, gene regulation, etc. p38MAPK is a common pathway involved in all the neurodegenerative disease and glaucoma as well, and more research in this direction can be really beneficial for the development of novel diagnostic and therapeutic measures.
authors: Government Medical College and Hospital, Sector 32, Chandigarh, India. vishaljindal87@gmail.com
authors: Vishal
authors: V
authors: Jindal
mesh_terms: D000818:Animals; D002908:Chronic Disease; D005901:Glaucoma / Q000473:pathology*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000473:pathology*
references: Jpn J Ophthalmol. 2005 Mar-Apr;49(2):106-8
references: 15838725
references: Postepy Biochem. 2012;58(1):79-90
references: 23214132
references: Am J Neurodegener Dis. 2012;1(2):168-79
references: 23024928
references: Am J Ophthalmol. 1998 Oct;126(4):498-505
references: 9780094
references: J Neurochem. 2002 Aug;82(3):655-65
references: 12153489
references: Neurochem Int. 2006 Apr;48(5):404-14
references: 16442670
references: Mol Vis. 2008 Jan 31;14:224-33
references: 18334938
references: Prog Retin Eye Res. 2006 Sep;25(5):490-513
references: 16962364
references: J Signal Transduct. 2012;2012:649079
references: 22792454
references: Adv Neurol. 2001;86:83-9
references: 11554012
references: Lipids. 2001 Sep;36(9):945-59
references: 11724467
references: Mov Disord. 1994 Mar;9(2):125-38
references: 8196673
references: Curr Opin Ophthalmol. 2000 Apr;11(2):116-20
references: 10848217
references: Eur J Neurosci. 2005 Aug;22(3):617-26
references: 16101743
references: Eye (Lond). 2002 Mar;16(2):209-12
references: 11988832
references: Neurol Clin. 1996 May;14(2):317-35
references: 8827174
references: Am J Ophthalmol. 2002 Jan;133(1):135-7
references: 11755850
references: Neurotoxicology. 2002 Oct;23(4-5):487-502
references: 12428721
references: J Neurol Sci. 2006 Jul 15;246(1-2):79-83
references: 16564058
references: Can J Ophthalmol. 2008 Feb;43(1):53-60
references: 18219347
references: Biochim Biophys Acta. 1973 Oct 5;320(3):681-6
references: 4356538
references: J Neurochem. 2008 Oct;107(1):279-90
references: 18691390
references: JAMA. 2003 Apr 23-30;289(16):2094-103
references: 12709467
references: Mol Vis. 2012;18:2127-36
references: 22876140
references: FASEB J. 2008 Apr;22(4):1213-25
references: 18032633
references: J Cell Biol. 2006 Mar 13;172(6):799-801
references: 16533942
references: Curr Eye Res. 2010 Sep;35(9):828-34
references: 20795865
references: Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10858-63
references: 16040805
references: J Neurochem. 2006 Jun;97(6):1634-58
references: 16805774
references: Curr Opin Pharmacol. 2013 Feb;13(1):12-5
references: 23069478
references: Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13444-9
references: 17684098
references: Brain Res. 2005 May 31;1045(1-2):185-98
references: 15910777
references: Eur J Ophthalmol. 2003 Apr;13 Suppl 3:S32-5
references: 12749675
references: Br J Ophthalmol. 2006 Mar;90(3):262-7
references: 16488940
references: Rom J Intern Med. 2011;49(1):55-8
references: 22026253
references: J Nutr Health Aging. 2006 Sep-Oct;10(5):386-99
references: 17066210
references: Mol Vis. 2012;18:2828-38
references: 23233785
references: Eur Neurol. 2002;47(3):165-8
references: 11914555
references: J Neurosci. 2009 Oct 14;29(41):12957-69
references: 19828810
references: Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5085-90
references: 17962460
references: Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1077-87
references: 11923249
references: Curr Opin Lipidol. 2002 Apr;13(2):155-64
references: 11891418
references: Neuron. 2004 Sep 2;43(5):633-45
references: 15339646